TY - JOUR
T1 - Biomarker-driven and molecular targeted therapies for colorectal cancers
AU - Schirripa, Marta
AU - Cohen, Stacey A.
AU - Battaglin, Francesca
AU - Lenz, Heinz Josef
PY - 2017/7/4
Y1 - 2017/7/4
N2 - Improved clinical selection and identification of new molecules and innovative strategies have widened treatment options and increased overall survival in metastatic colorectal cancer patients in recent years. Biomarker-driven therapies represent an emerging issue in this field and new targeted treatments are under investigation and probably will be soon adopted into daily clinical practice. In the present review, the role RAS, BRAF mutations, Her2 amplification, microsatellite instability, and CpG island methylator phenotype are discussed according to their possible roles as prognostic, predictive markers, as well as possible biomarker-driven treatment options.
AB - Improved clinical selection and identification of new molecules and innovative strategies have widened treatment options and increased overall survival in metastatic colorectal cancer patients in recent years. Biomarker-driven therapies represent an emerging issue in this field and new targeted treatments are under investigation and probably will be soon adopted into daily clinical practice. In the present review, the role RAS, BRAF mutations, Her2 amplification, microsatellite instability, and CpG island methylator phenotype are discussed according to their possible roles as prognostic, predictive markers, as well as possible biomarker-driven treatment options.
KW - BRAF
KW - CpG island methylator phenotype
KW - HER2
KW - Microsatellite instability
KW - RAS
UR - http://www.scopus.com/inward/record.url?scp=85028323875&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85028323875&partnerID=8YFLogxK
U2 - 10.1053/j.seminoncol.2017.06.003
DO - 10.1053/j.seminoncol.2017.06.003
M3 - Article
AN - SCOPUS:85028323875
JO - Seminars in Oncology
JF - Seminars in Oncology
SN - 0093-7754
ER -